<DOC>
	<DOCNO>NCT01105130</DOCNO>
	<brief_summary>RATIONALE : L-arginine supplement may improve quality life erectile function men prostate cancer survivor . PURPOSE : This randomized phase II trial study well L-arginine supplementation work without enzyme inhibitor treat erectile function quality life prostate cancer survivor previously treat radiation therapy .</brief_summary>
	<brief_title>L-Arginine Supplementation With Without Enzyme Inhibitors Treating Erectile Function Prostate Cancer Survivors</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine `` best dose '' ( define dose show greatest improvement erectile function domain International Index Erectile Function [ IIEF ] 8 week therapy ) L-arginine/Korean ginseng/gingko biloba/damiana-based supplement ( L-arginine ) use subsequent phase III trial prostate cancer survivor previously treat radiotherapy . Secondary - Evaluate toxicity treatment L-arginine without phosphodiesterase-5 inhibitor . - Estimate trial accrual , retention , adherence , variability . - Assess change quality life ( QOL ) sexual function define change QOL patient use Expanded Prostate Cancer Index Composite , change domain IIEF ( i.e. , orgasmic function , sexual desire , intercourse satisfaction , overall satisfaction ) , change Sexual Encounter Profile , change percentage `` yes '' ( positive ) responses either two global efficacy question . OUTLINE : Patients stratify accord age ( &lt; 65 year vs ≥ 65 year ) current use phosphodiesterase-5 ( PDE-5 ) inhibitor ( yes v ) . Patients randomize 1 3 treatment arm . - Arm I : Patients receive oral placebo twice daily ( total 6 capsule per day ) . - Arm II : Patients receive oral L-arginine oral placebo twice daily ( total 3 capsule per day ) . - Arm III : Patients receive oral L-arginine twice daily ( total 6 capsule per day ) . In arm , treatment continue 8 week absence unacceptable toxicity . Patients may also receive oral sildenafil , tadalafil , vardenafil ( PDE-5 inhibitor ) . Patients complete International Index Erectile Function Expanded Prostate Cancer Index Composite-26 baseline week 4 8 . Patients also complete Sexual Encounter Profile Questionnaire , FACT-P , Global Efficacy Questionnaire week 4 8 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>INCLUSION CRITERIA : Male prostate cancer survivor previously treat radiotherapy identifies concern sexual quality life , include erectile dysfunction . ( seed implant eligible ) Had successful sexual activity prior commencement radiotherapy . Erectile dysfunction , define inability achieve maintain erection sufficient satisfactory sexual performance Interested sexual activity agrees make least one sexual intercourse attempt partner every week study . The usage PDE5 inhibitor voluntary serve stratification factor . Patients take PDE5 inhibitor must agree assume responsibility cost PDE5 inhibitor treatment protocol period ( 8 week period ) cover cost trial . Patients currently take PDE5 inhibitor sildenafil ( Viagra® , Pfizer Pharmaceuticals ) , tadalafil ( Cialis® , Lilly ICOS , LLC ) , vardenafil ( Levitra® , Bayer Healthcare / Schering Plough Corp. ) must agree take medication prescribed treat physician . Patients take PDE5 inhibitor part study must stable dose drug least one month prior study entry . Must able take oral medication . &gt; 6 month follow completion cancer therapy No evidence prostate cancer Prior malignancy allow evidence recurrent disease . If previously take LHRH agonist androgen suppression ( e.g , Lupron , Zoladex ) , antiandrogen ( e.g. , Casodex , Eulexin , Nilandron ) , estrogenic ( e.g. , diethylstilbestrol ) agent , serum testosterone must return laboratory normal range No plan surgery protocol 4 week follow completion protocol Prior cystoscopy permit . Age &gt; 18 ECOG performance status 0/1 . Patients must agree start take herbal product erectile dysfunction eight week study intervention . EXCLUSION CRITERIA : No concurrent erectile dysfunction therapy permit ( i.e . vacuum pump , cavernosal injection , drug therapy ) . Past use therapy permit patient meet inclusion criterion . No testosterone supplementation permit . Use LHRH agonist androgen suppression ( e.g , Lupron , Zoladex ) , anti androgen ( e.g. , Casodex , Eulexin , Nilandron ) , estrogenic ( e.g. , diethylstilbestrol ) agent within last 6 month . Prior prostate lower genitourinary surgery ( bladder , penis , urethra , testicle ) include transurethral resection prostate ( TURP ) . ( Prior vasectomy allow ) Serious cardiovascular disease ( unstable angina , supraventricular arrhythmia , myocardial infarction , symptomatic congestive heart failure , cardiac arrhythmia , coronary artery bypass surgery within 6 month prior registration ) . Hypotension ( &lt; 90/50mm Hg ) , uncontrolled hypertension ( &gt; 170/100 mm Hg ) Stroke spinal cord injury within 6 month registration . Patients Persantine , heparin , Lovenox , warfarin , ginkgo biloba , Plavix , Disalcid , bloodthinning medication history bleed disorder exclude . ( Aspirin &lt; 325mg allow ) Current use cimetidine , ketoconazole , itraconazole , erythromycin , ritonavir . Major medical psychiatric illness , opinion investigator , would prevent completion treatment would interfere followup . Current prior use organic nitrate within last 6 month ( e.g. , use nitroglycerin ) May receive investigational agent device 30 day prior start study drug . History allergic reaction attribute compound similar chemical biologic composition ArginMax ( larginine , ginseng , ginkgo biloba )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>radiation toxicity</keyword>
	<keyword>male erectile disorder</keyword>
	<keyword>prostate cancer</keyword>
</DOC>